Literature DB >> 30705246

Hypoxia-Associated Factor (HAF) Mediates Neurofibromin Ubiquitination and Degradation Leading to Ras-ERK Pathway Activation in Hypoxia.

Yangsook Song Green1, Timothy Sargis2, Ethan Conrad Reichert1, Eleanor Rudasi1, Daniel Fuja1, Eric Jonasch3, Mei Yee Koh4.   

Abstract

Low oxygen or hypoxia is a feature of all solid tumors and has been associated with aggressive disease. Here, we describe a novel mechanism for the hypoxia-dependent degradation of the Ras-GTPase-activating protein neurofibromin, by hypoxia-associated factor (HAF). We have previously characterized HAF as an oxygen-independent ubiquitin ligase for HIF-1α. Here, we show that HAF promotes neurofibromin ubiquitination and degradation independently of oxygen and pVHL, resulting in Ras-ERK pathway activation. Hypoxia enhanced HAF:neurofibromin binding independently of HAF-SUMOylation, whereas HAF knockdown increased neurofibromin levels primarily in hypoxia, supporting the role of HAF as a hypoxia-specific neurofibromin regulator. HAF overexpression increased p-ERK levels and promoted resistance of clear cell kidney cancer (ccRCC) cells to sorafenib and sunitinib in both normoxia and hypoxia. However, a greater-fold increase in sorafenib/sunitinib resistance was observed during hypoxia, particularly in pVHL-deficient cells. Intriguingly, HAF-mediated resistance was HIF-2α-dependent in normoxia, but HIF-2α-independent in hypoxia indicating two potential mechanisms of HAF-mediated resistance: a HIF-2α-dependent pathway dominant in normoxia, and the direct activation of the Ras-ERK pathway through neurofibromin degradation dominant in hypoxia. Patients with ccRCC with high HAF transcript or protein levels showed significantly decreased overall survival compared with those with low HAF. Thus, we establish a novel, nonmutational pathway of neurofibromin inactivation through hypoxia-induced HAF-mediated degradation, leading to Ras-ERK activation and poor prognosis in ccRCC. IMPLICATIONS: We describe a novel mechanism of neurofibromin degradation induced by hypoxia that leads to activation of the prooncogenic Ras-ERK pathway and resistance to therapy. ©2019 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 30705246      PMCID: PMC6497562          DOI: 10.1158/1541-7786.MCR-18-1080

Source DB:  PubMed          Journal:  Mol Cancer Res        ISSN: 1541-7786            Impact factor:   5.852


  49 in total

1.  The hypoxia-associated factor switches cells from HIF-1α- to HIF-2α-dependent signaling promoting stem cell characteristics, aggressive tumor growth and invasion.

Authors:  Mei Yee Koh; Robert Lemos; Xiuping Liu; Garth Powis
Journal:  Cancer Res       Date:  2011-04-21       Impact factor: 12.701

Review 2.  The NF1 somatic mutational landscape in sporadic human cancers.

Authors:  Charlotte Philpott; Hannah Tovell; Ian M Frayling; David N Cooper; Meena Upadhyaya
Journal:  Hum Genomics       Date:  2017-06-21       Impact factor: 4.639

3.  Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5.

Authors:  Li Liu; Yichen Cao; Charles Chen; Xiaomei Zhang; Angela McNabola; Dean Wilkie; Scott Wilhelm; Mark Lynch; Christopher Carter
Journal:  Cancer Res       Date:  2006-12-15       Impact factor: 12.701

Review 4.  Targeting hypoxia in cancer therapy.

Authors:  William R Wilson; Michael P Hay
Journal:  Nat Rev Cancer       Date:  2011-06       Impact factor: 60.716

5.  Hypoxia-induced SUMOylation of E3 ligase HAF determines specific activation of HIF2 in clear-cell renal cell carcinoma.

Authors:  Mei Yee Koh; Vuvi Nguyen; Robert Lemos; Bryant G Darnay; Galina Kiriakova; Mena Abdelmelek; Thai H Ho; Jose Karam; Federico A Monzon; Eric Jonasch; Garth Powis
Journal:  Cancer Res       Date:  2014-11-24       Impact factor: 12.701

6.  Role of ERK and calcium in the hypoxia-induced activation of HIF-1.

Authors:  Denis Mottet; Gaetan Michel; Patricia Renard; Noelle Ninane; Martine Raes; Carine Michiels
Journal:  J Cell Physiol       Date:  2003-01       Impact factor: 6.384

7.  HIF2α acts as an mTORC1 activator through the amino acid carrier SLC7A5.

Authors:  Ainara Elorza; Inés Soro-Arnáiz; Florinda Meléndez-Rodríguez; Victoria Rodríguez-Vaello; Glenn Marsboom; Guillermo de Cárcer; Bárbara Acosta-Iborra; Lucas Albacete-Albacete; Angel Ordóñez; Leticia Serrano-Oviedo; Jose Miguel Giménez-Bachs; Alicia Vara-Vega; Antonio Salinas; Ricardo Sánchez-Prieto; Rafael Martín del Río; Francisco Sánchez-Madrid; Marcos Malumbres; Manuel O Landázuri; Julián Aragonés
Journal:  Mol Cell       Date:  2012-10-25       Impact factor: 17.970

8.  Induction of endothelial PAS domain protein-1 by hypoxia: characterization and comparison with hypoxia-inducible factor-1alpha.

Authors:  M S Wiesener; H Turley; W E Allen; C Willam; K U Eckardt; K L Talks; S M Wood; K C Gatter; A L Harris; C W Pugh; P J Ratcliffe; P H Maxwell
Journal:  Blood       Date:  1998-10-01       Impact factor: 22.113

Review 9.  Clinical and genetic aspects of neurofibromatosis 1.

Authors:  Kimberly Jett; Jan M Friedman
Journal:  Genet Med       Date:  2010-01       Impact factor: 8.822

10.  An oxygen-regulated switch in the protein synthesis machinery.

Authors:  James Uniacke; Chet E Holterman; Gabriel Lachance; Aleksandra Franovic; Mathieu D Jacob; Marc R Fabian; Josianne Payette; Martin Holcik; Arnim Pause; Stephen Lee
Journal:  Nature       Date:  2012-05-06       Impact factor: 49.962

View more
  6 in total

1.  Macrophage HIF-1α Is an Independent Prognostic Indicator in Kidney Cancer.

Authors:  Sophie J Cowman; Daniel G Fuja; Xian-De Liu; Rebecca S Slack Tidwell; Neelima Kandula; Deepika Sirohi; Archana M Agarwal; Lyska L Emerson; Sheryl R Tripp; Jeffrey S Mohlman; Miekan Stonhill; Guillermina Garcia; Christopher J Conley; Adam A Olalde; Timothy Sargis; Adela Ramirez-Torres; Jose A Karam; Christopher G Wood; Kanishka Sircar; Pheroze Tamboli; Kenneth Boucher; Benjamin Maughan; Benjamin T Spike; Thai H Ho; Neeraj Agarwal; Eric Jonasch; Mei Yee Koh
Journal:  Clin Cancer Res       Date:  2020-06-25       Impact factor: 12.531

2.  Hypoxia Transcriptomic Modifications Induced by Proton Irradiation in U87 Glioblastoma Multiforme Cell Line.

Authors:  Valentina Bravatà; Walter Tinganelli; Francesco P Cammarata; Luigi Minafra; Marco Calvaruso; Olga Sokol; Giada Petringa; Giuseppe A P Cirrone; Emanuele Scifoni; Giusi I Forte; Giorgio Russo
Journal:  J Pers Med       Date:  2021-04-16

Review 3.  Neurofibromin Structure, Functions and Regulation.

Authors:  Mohammed Bergoug; Michel Doudeau; Fabienne Godin; Christine Mosrin; Béatrice Vallée; Hélène Bénédetti
Journal:  Cells       Date:  2020-10-27       Impact factor: 6.600

Review 4.  Focus on Hypoxia-Related Pathways in Pediatric Osteosarcomas and Their Druggability.

Authors:  Marina Pierrevelcin; Quentin Fuchs; Benoit Lhermitte; Melissa Messé; Eric Guérin; Noelle Weingertner; Sophie Martin; Isabelle Lelong-Rebel; Charlotte Nazon; Monique Dontenwill; Natacha Entz-Werlé
Journal:  Cells       Date:  2020-08-31       Impact factor: 6.600

5.  Neurofibromin Deficiency Causes Epidermal Growth Factor Receptor Upregulation through the Activation of Ras/ERK/SP1 Signaling Pathway in Neurofibromatosis Type 1-Associated Malignant Peripheral Nerve Sheet Tumor.

Authors:  Gun-Hoo Park; Su-Jin Lee; Chang-Gun Lee; Jeonghyun Kim; Eunkuk Park; Seon-Yong Jeong
Journal:  Int J Mol Sci       Date:  2021-12-10       Impact factor: 5.923

6.  The NEDD8-activating enzyme inhibitor MLN4924 reduces ischemic brain injury in mice.

Authors:  Huilin Yu; Haiyu Luo; Luping Chang; Shisheng Wang; Xue Geng; Lijing Kang; Yi Zhong; Yongliang Cao; Ranran Wang; Xing Yang; Yuanbo Zhu; Mei-Juan Shi; Yue Hu; Zhongwang Liu; Xuhui Yin; Yunwei Ran; Hao Yang; Wenying Fan; Bing-Qiao Zhao
Journal:  Proc Natl Acad Sci U S A       Date:  2022-02-08       Impact factor: 11.205

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.